Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Integrated Surgical Systems

This article was originally published in The Gray Sheet

Executive Summary

Robotic surgery products maker announces Sept. 22 that FDA may reclassify its Robodoc surgical assistant system from Class III to Class II. Reclassification would allow the product to be cleared to market through the 510(k) process. Data generated from the DigiMatch Robodoc system multicenter clinical trial will be used to support the reclassification submission, ISS says. In May, agency officials notified competitor Intuitive Surgical that it could submit a 510(k) for cardiovascular use of the da Vinci tele-robotic endoscopic surgical system, rather than proceeding through the premarket approval application process (1"The Gray Sheet" July 17, 2000, p. 12)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel